ClinicalTrials.gg
CompletedNCT00686790Updated Apr 6, 2017Results posted

Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)

A Phase 3 interventional study of Peginterferon alfa-2b (PegIntron, SCH 54031) in Hepatitis D, Chronic and Hepatitis B, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to determine the effectiveness of peginterferon alfa-2b 1.5 mcg/kg/week administered for 52 weeks (wk) in previously untreated participants coinfected with hepatitis virus B and D. After 52-week treatment and 52-week follow-up, the virologic, biochemical, and histological response will be evaluated.

02

Conditions studied

  • Hepatitis D, Chronic
  • Hepatitis B, Chronic

Keywords

  • Hepatitis D
  • Hepatitis B
03

In context

Hepatitis D, Chronic

43 studies on the registry are indexed under Hepatitis D, Chronic; 9 are open to participants now.

This study's enrollment of 68 is above the median of 46 across 30 interventional studies indexed under Hepatitis D, Chronic.

Browse Hepatitis D, Chronic studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Age 18-65 years old.
  • positive >6 months.
  • >= 2 >6 months.
  • HDV RNA positive serology.
  • Serum antibody to hepatitis delta antigen of IgG and IgM class.
  • Knodell score HAI >= 6 and F >= 0; positive test for intrahepatic Delta antigen in liver .
  • Women of (includes women who are less than 1 year and women who become sexually active) must be using an acceptable method of (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
  • Participants must be free of any disease (other than chronic hepatitis B and D), that would interfere with study evaluations.
  • Participants must understand and be able to adhere to the dosing and visit schedules, and agree to record symptom severity scores, medication times, concomitant medications, and adverse events accurately and consistently in a daily diary.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 and >65.
  • Concomitant and/or infection.
  • Actual liver failure (total serum >2.5 x normal, prolonged >3 sec, serum albumin \<3 g/dl, history of ascites, variceal bleeding, or hepatic encephalopathy).
  • Toxic or hepatitis (ANA titers > 1:160), metabolic liver diseases (Wilson disease, hemochromatosis, α-1 antitrypsin deficiency)
  • Women who are pregnant or nursing.
  • Leukopenia (\<2500/mm\^3), neutropenia (\<1000/mm\^3), \<10 g/dl, presence of other severe diseases (myocardiopathy, diabetes mellitus, arterial hypertension, neoplasia, neurologic diseases, malnutrition).
  • Antiviral, immunomodulatory, , or chemotherapeutical treatment within 6 months of the participation in the study.
  • Depression and/or psychiatric disorders.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    PegIntron

    All participants received PegIntron (Peginterferon alfa-2b) weekly based on their body weight.

    Biological: Peginterferon alfa-2b (PegIntron, SCH 54031)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Virological Response

    For virological response, a participant was defined as a responder if his/her serum sample tested negative for Hepatitis D Virus - ribonucleic acid (HDV-RNA) by polymerase chain reaction (PCR) at end of treatment (EOT).

    Time frame: 52 weeks (end of treatment [EOT]), 104 weeks (end of follow-up [EOF]) following treatment initiation

  2. Number of Participants With a Biochemical Response

    A participant was defined as a responder if his alanine aminotransferase (ALT) level after 52 weeks, i.e. at EOT, was below the upper reference range as specified by Bioclinica. The normal reference range for ALT is 5-55 U/L.

    Time frame: 52 weeks (EOT), 104 weeks (EOF)

  3. Number of Participants With a Combined Response

    The combined response was defined as an ALT level below the upper reference range and a negative HDV-RNA test. The normal reference range for ALT is 5-55 U/L.

    Time frame: 52 weeks (EOT), 104 weeks (EOF)

Secondary outcomes

  1. Number of Participants With Hepatitis B Virus (HBV) Replication Response (HBV Response)

    Serum samples collected from the participants were tested by PCR to detect HBV-DNA. HBV response was defined as the absence of HBV-deoxyribonucleic acid (HBV-DNA) in serum.

    Time frame: 52 week (EOT)

  2. Number of Participants With a Liver Histology Response

    The liver histology response was defined as at least a 2 point decrease in the necrosis inflammation score (a sum of periportal necrosis \[0-10\], lobular inflammation \[0-4\], portal inflammation \[0-4\], with the total score of 18 representing the worst outcome) and no increase or regression of fibrosis (scored \[0-4\]) in the pre- and post-treatment liver biopsies. The efficacy of treatment based on histological response was assessed by the investigator as complete response, partial response, minimal response, progressive disease, and not assessable at EOT.

    Time frame: Baseline and 52 week (EOT)

07

Results

Posted Jan 17, 2011

Participant flow

Participant flow — Overall Study
MilestonePegIntron
Started48
Completed32
Not completed16
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Withdrew: Death1
Withdrew: Lost to follow-up12

Outcome measures

PrimaryNumber of Participants With a Virological Response

For virological response, a participant was defined as a responder if his/her serum sample tested negative for Hepatitis D Virus - ribonucleic acid (HDV-RNA) by polymerase chain reaction (PCR) at end of treatment (EOT).

Time frame:
52 weeks (end of treatment [EOT]), 104 weeks (end of follow-up [EOF]) following treatment initiation
Reported as:
Number · Participants
Number of Participants With a Virological Response
ParticipantsPegIntron
Responders at 52 weeks12
Non-responders at 52 weeks24
Responders at 104 weeks9
Non-responders at 104 weeks27
SecondaryNumber of Participants With Hepatitis B Virus (HBV) Replication Response (HBV Response)

Serum samples collected from the participants were tested by PCR to detect HBV-DNA. HBV response was defined as the absence of HBV-deoxyribonucleic acid (HBV-DNA) in serum.

Time frame:
52 week (EOT)
Reported as:
Number · Participants
Number of Participants With Hepatitis B Virus (HBV) Replication Response (HBV Response)
ParticipantsPegIntron
Responders6
Non responders30
PrimaryNumber of Participants With a Biochemical Response

A participant was defined as a responder if his alanine aminotransferase (ALT) level after 52 weeks, i.e. at EOT, was below the upper reference range as specified by Bioclinica. The normal reference range for ALT is 5-55 U/L.

Time frame:
52 weeks (EOT), 104 weeks (EOF)
Reported as:
Number · Participants
Number of Participants With a Biochemical Response
ParticipantsPegIntron
Responders at 52 weeks18
Non-responders at 52 weeks14
Responders at 104 weeks9
Non-responders at 104 weeks23
PrimaryNumber of Participants With a Combined Response

The combined response was defined as an ALT level below the upper reference range and a negative HDV-RNA test. The normal reference range for ALT is 5-55 U/L.

Time frame:
52 weeks (EOT), 104 weeks (EOF)
Reported as:
Number · Participants
Number of Participants With a Combined Response
ParticipantsPegIntron
Responders at 52 weeks7
Non-responders at 52 weeks25
Responders at 104 weeks6
Non-responders at 104 weeks26
SecondaryNumber of Participants With a Liver Histology Response

The liver histology response was defined as at least a 2 point decrease in the necrosis inflammation score (a sum of periportal necrosis \[0-10\], lobular inflammation \[0-4\], portal inflammation \[0-4\], with the total score of 18 representing the worst outcome) and no increase or regression of fibrosis (scored \[0-4\]) in the pre- and post-treatment liver biopsies. The efficacy of treatment based on histological response was assessed by the investigator as complete response, partial response, minimal response, progressive disease, and not assessable at EOT.

Time frame:
Baseline and 52 week (EOT)
Reported as:
Number · Participants
Number of Participants With a Liver Histology Response
ParticipantsPegIntron
Complete response10
Partial response14
Minimal response6
Progressive disease3
Response not assessable3

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PegIntron—3/49 (6.1%)47/49 (95.9%)
Most frequent serious events
Most frequent serious events
EventPegIntron
PANCREATITISGastrointestinal disorders1/49
PYREXIAGeneral disorders1/49
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/49
ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations1/49
INTERSTITIAL LUNG DISEASERespiratory, thoracic and mediastinal disorders1/49
Most frequent other events
Showing 10 of 32
Most frequent other events
EventPegIntron
PYREXIAGeneral disorders38/49
HEADACHENervous system disorders38/49
CHILLSGeneral disorders32/49
MYALGIAMusculoskeletal and connective tissue disorders32/49
FATIGUEGeneral disorders26/49
ARTHRALGIAMusculoskeletal and connective tissue disorders22/49
NAUSEAGastrointestinal disorders18/49
ASTHENIAGeneral disorders16/49
DIZZINESSNervous system disorders15/49
ANOREXIAMetabolism and nutrition disorders14/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)PegIntron
Mean37.55 ± 12.48
Sex: Female, Male
Sex: Female, Male(Participants)PegIntron
Female22
Male26
Region of Enrollment
Region of Enrollment(Participants)PegIntron
Romania48
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
Start
Dec 2005
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jan 17, 2011
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00686790
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Dec 2005
Primary completion
May 2009
Completion
May 2009
Results posted
Jan 17, 2011
Last update
Apr 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2b

Start the discussion